 Molecular Partners AG NASDAQ: MOLN entered into a license agreement with Novartis AG NYSE: NVS to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies DARPin-RLTs. According to the license agreement, Novartis will pay 20 million upfront to Molecular Partners. 